VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 71 filers reported holding VERONA PHARMA PLC in Q3 2022. The put-call ratio across all filers is 0.34 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,563,569 | -9.5% | 586,722 | +17.3% | 0.11% | -10.4% |
| Q2 2023 | $10,570,000 | -69.8% | 500,000 | -71.3% | 0.12% | -73.7% |
| Q1 2023 | $35,024,821 | +436.2% | 1,744,264 | +597.7% | 0.48% | +447.1% |
| Q4 2022 | $6,532,500 | +70.4% | 250,000 | -33.3% | 0.09% | +61.1% |
| Q3 2022 | $3,833,000 | +82.4% | 375,033 | -25.2% | 0.05% | +68.8% |
| Q2 2022 | $2,101,000 | – | 501,458 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,249,918 | $69,273,663 | 7.59% |
| Aisling Capital Management LP | 1,115,352 | $18,180,238 | 7.49% |
| NEA Management Company, LLC | 5,108,563 | $91,031,474 | 7.03% |
| Octagon Capital Advisors LP | 2,369,000 | $38,614,700 | 5.93% |
| Knoll Capital Management, LLC | 200,000 | $3,260,000 | 3.38% |
| Frazier Life Sciences Management, L.P. | 3,014,349 | $49,133,889 | 3.26% |
| Perceptive Advisors | 4,007,197 | $65,317,311 | 2.18% |
| RA Capital Management | 6,317,990 | $102,983,237 | 2.03% |
| Deep Track Capital, LP | 3,187,415 | $51,954,865 | 2.00% |
| Carlyle Group Inc. | 2,457,500 | $40,008,100 | 1.74% |